Inspire Medical Systems appoints new vice president of investor relations
Sleep apnea medical tech firm Inspire Medical Systems has named Ezgi Yagci as its new vice president of IR.
Yagci joins the NYSE-listed company, which is focused on the ‘development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea,’ from Zimmer Biomet, where she served as IR manager.
‘The team is very excited to welcome Ezgi and her vast experience in the medical technology sector to Inspire,’ says Tim Herbert, president and CEO, in a statement welcoming Yagci to the company.
‘She will have a positive impact on our expanding investor relations program and play a key role in contributing to the overall strategy of the organization,’ he adds.
Yagci joined Zimmer Biomet in July 2020 and brings more than 15 years’ institutional investment experience to her new role at Inspire.
During her stint at Zimmer Biomet, Yagci was responsible for earnings preparation, investment conference participation, sell-side interactions and targeted, proactive shareholder outreach and engagement, according to the release announcing her move to Inspire.
Yagci was also ‘instrumental’ in Zimmer Biomet’s ESG disclosures while ‘researching, benchmarking and enhancing the company’s annual sustainability report’.
During her time on the buy side, Yagci had a focus on medical devices and healthcare services, while working in ‘senior roles at multiple top-tier investment firms,’ including Balyasny Asset Management, Green Arrow Capital Management (Millennium Management), TIAA-CREF, Partner Fund Management and RS Investments.
‘I am thrilled to join the team at Inspire, especially as the company anticipates important product innovations and enhancements that will fuel its further growth,’ says Yagci, who holds both master's and bachelor of arts degrees in economics, as well as a bachelor of arts in international relations – all from Boston University.
‘I look forward to contributing to Inspire’s mission of serving the many patients with untreated obstructive sleep apnea.’